&lt;p&gt;Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China&lt;/p&gt;

Men, Peng; Liu, Tianbi; Zhai, Suodi

doi:10.2147/dmso.s266901

Cited by 13 publications

(10 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, given the recent increase in diabetes incidence at a younger age due to lifestyle changes, 114 the actual earnings and expenses affected by the reduction or cessation of work productivity should also be evaluated. In parallel with several successful RCT results showing a risk reduction of cardiovascular and renal events with SGLT2i in patients with T2DM, several studies using a simulation model suggested better cost‐effectiveness of SGLT2i compared to that of non‐SGLT2i treatment when used in addition to the standard of care 115–121 . Moreover, an observational study using a database in the US and Sweden demonstrated lower healthcare costs of SGLT2i initiation compared to those of DPP4‐i or other non‐SGLT2i treatments 122,123 .…”

Section: Recent Diabetes Studies In Japanmentioning

confidence: 85%

“…In parallel with several successful RCT results showing a risk reduction of cardiovascular and renal events with SGLT2i in patients with T2DM, several studies using a simulation model suggested better cost-effectiveness of SGLT2i compared to that of non-SGLT2i treatment when used in addition to the standard of care. [115][116][117][118][119][120][121] Moreover, an observational study using a database in the US and Sweden demonstrated lower healthcare costs of SGLT2i initiation compared to those of DPP4-i or other non-SGLT2i treatments. 122,123 Although the Japanese database has the strength of detailed information regarding cost, healthcare cost-related studies remain limited, including indirect cost analysis and the quality-adjusted life years.…”

Section: Diabetes-related Healthcare Costsmentioning

confidence: 99%

See 1 more Smart Citation

Current trends in diabetes mellitus database research in Japan

Kohsaka

Morita

Okami

et al. 2021

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

With the widespread use of electronic medical records and administrative claims databases, analytic results from so‐called real‐world data have become increasingly important in healthcare decision‐making. Diabetes mellitus is a heterogeneous condition that involves a broad spectrum of patients. Real‐world database studies have been recognised as a powerful tool to understand the impact of current practices on clinical courses and outcomes, such as long‐term glucose control, development of microvascular or macro‐vascular diseases, and mortality. Diabetes is also a major global health issue and poses a significant social and economic burden worldwide. Therefore, it is critical to understand the epidemiology, clinical course, treatment reality, and long‐term outcomes of diabetes to determine realistic solutions to a variety of disease‐related issues that we are facing. In the present review, we summarise the healthcare system and large‐scale databases currently available in Japan, introduce the results from recent database studies involving Japanese patients with diabetes, and discuss future opportunities and challenges for the use of databases in the management of diabetes.

show abstract

Section: Recent Diabetes Studies In Japanmentioning

confidence: 85%

Section: Diabetes-related Healthcare Costsmentioning

confidence: 99%

Current trends in diabetes mellitus database research in Japan

Kohsaka

Morita

Okami

et al. 2021

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Hospitalization was found to be one of the two largest contributors to direct costs of type 2 diabetes in economically developed countries 31 , which supports similar findings from the American Diabetes Association 3 . Cost-effectiveness modeling analyses suggest that empagliflozin is a highly cost-effective treatment in Japan 32 and China 33,34 . Given the economic burden of type 2 diabetes, the impact of empagliflozin on medical costs in routine clinical care will be analyzed for individual countries in the EMPRISE East Asia study.…”

Section: Discussionmentioning

confidence: 99%

Healthcare resource utilization in patients treated with empagliflozin in East Asia

Sheu

Seino

Tan

et al. 2022

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction We investigated the utilization of healthcare resources in patients with type 2 diabetes treated with empagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor, versus dipeptidyl peptidase‐4 (DPP‐4) inhibitors in clinical practice in Japan, South Korea, and Taiwan. Materials and Methods We analyzed the Japanese Medical Data Vision database (December 2014–April 2018), the South Korean National Health Information Database, and the Taiwanese National Health Insurance claims database (both May 2016–December 2017). Patients with type 2 diabetes starting empagliflozin, 10 or 25 mg, or a DPP‐4 inhibitor were matched 1:1 via propensity scores (PS). We compared inpatient care needs, emergency room (ER) visits, and outpatient visits between the treatment groups using Poisson regression and Cox proportional hazards models, pooled across countries by random‐effects meta‐analysis. Results We identified 28,712 pairs of PS‐matched patients; the mean follow‐up was 5.7–6.8 months. Empagliflozin‐treated patients had a 27% lower risk of all‐cause hospitalization compared with DPP‐4 inhibitor–treated patients (rate ratio [RR] 0.73, 95% CI 0.67–0.79), and 23% reduced risk for first hospitalization (hazard ratio 0.77, 95% CI 0.73–0.81). The risk for an ER visit was 12% lower with empagliflozin than with DPP‐4 inhibitors (RR 0.88, 95% CI 0.83–0.94) while the risk for outpatient visit was 4% lower (RR 0.96, 95% CI 0.96–0.97). These findings were generally consistent across countries, regardless of baseline cardiovascular disease, and in the subgroup starting empagliflozin with the 10 mg dose. Conclusions Empagliflozin treatment was associated with lower inpatient care needs and other healthcare resource utilization than DPP‐4 inhibitors in routine clinical practice in East Asia in this study.

show abstract

“…Only one study evaluating the cost-effectiveness of empagliflozin versus standard of care in adult patients with T2D and high risk of CVD in Chinese population was identified in the public domain [ 18 ]. This study was conducted using a patient level simulation model developed in MS Excel, based on the EMPA-REG OUTCOME trial data, and assessed rates of outcome, events, costs, LYs, QALYs, and ICER.…”

Section: Discussionmentioning

confidence: 99%

“…Chinese FDA). However, due to the relatively higher prices compared to other conventional oral antidiabetic drugs, treatment with empagliflozin may impose a potential economic impact on the healthcare payer [ 18 ]. Despite the rapid increase in the prevalence and economic burden of diabetes in China, Mao and colleagues have highlighted that a national strategy or special financing mechanism to meet these challenges is lacking in China [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Ramos¹,

Men

Wang

et al. 2021

Cost Eff Resour Alloc

Self Cite

View full text Add to dashboard Cite

Background In several cardiovascular outcome trials (CVOTs), empagliflozin (SGLT-2 inhibitor), sitagliptin (DPP-4 inhibitor) and liraglutide (GLP-1 receptor agonist) + standard of care (SoC) were compared to SoC in patients with type 2 diabetes and established cardiovascular disease (CVD). This study assessed the cost-effectiveness (CE) of empagliflozin + SoC in comparison to sitagliptin + SoC and liraglutide + SoC based on the respective CVOT. Methods The IQVIA Core Diabetes Model (CDM) was calibrated to reproduce the CVOT outcomes. EMPA-REG OUTCOME baseline characteristics and CVOT specific treatment effects on risk factors for cardiovascular disease (HbA1c, BMI, blood pressure, lipids) were applied. Three-year observed cardiovascular events of empagliflozin + SoC versus sitagliptin + SoC and liraglutide + SoC were derived from EMPA-REG OUTCOME and an indirect treatment comparison. Relative risk adjustments to calibrate the CDM were obtained after a trial and error process to match as closely the observed and CDM-predicted outcomes. The drug-specific treatment effects were considered up until HbA1c reached 8.5% and treatment switch occurred. After this switch, the United Kingdom Prospective Diabetes Study 82 risk equations predicted events based on co-existing risk factors and treatment intensification to basal bolus insulin were applied. The analysis was conducted from the perspective of the Chinese healthcare system applying 3% discounting. The time horizon was lifelong. Results Empagliflozin + SoC provides additional Quality Adjusted Life years (QALY + 0.564) for an incremental cost of 42,497RMB (US$6053) compared to sitagliptin + SoC, resulting in an Incremental Cost Utility Ratio of 75,349RMB (US$10,732), thus below the willingness-to-pay threshold of 212,676RMB, corresponding to three times the Gross Domestic Product in China (2019). Compared to liraglutide + SoC, empagliflozin + SoC use leads to 0.211QALY gained and cost savings of 71,427RMB (US$10,173) and is as such dominant. Scenario and probabilistic sensitivity analyses demonstrated the robustness of the results. Conclusion Results suggest that empagliflozin + SoC is cost-effective compared to sitagliptin + SoC and liraglutide + SoC at a willingness-to-pay threshold of 212,676RMB ($30,292)/QALY.

show abstract

<p>Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China</p>

Cited by 13 publications

References 42 publications

Current trends in diabetes mellitus database research in Japan

Current trends in diabetes mellitus database research in Japan

Healthcare resource utilization in patients treated with empagliflozin in East Asia

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Contact Info

Product

Resources

About